A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor proteins, and induces cancer cell death. A phase 1 dose-escalation study was initiated to examine the safety and efficacy o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Garzon, Ramiro, Savona, Michael, Baz, Rachid, Andreeff, Michael, Gabrail, Nashat, Gutierrez, Martin, Savoie, Lynn, Mau-Sorensen, Paul Morten, Wagner-Johnston, Nina, Yee, Karen, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Carlson, Robert, Rashal, Tami, Kashyap, Trinayan, Klebanov, Boris, Shacham, Sharon, Kauffman, Michael, Stone, Richard
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5524530/
https://ncbi.nlm.nih.gov/pubmed/28336527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-11-750158
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars